FibroBiologics (FBLG) Net Cash Flow (2023 - 2026)
FibroBiologics (FBLG) posted quarterly Net Cash Flow of $2.0 million for Q2 2026, up 1042.13% year-over-year from $178000.0 in Q2 2025, and up 159.58% on a QoQ basis from -$3.4 million in Q1 2026.
FibroBiologics (FBLG) Net Cash Flow (2023 - 2026) Analysis & Trends
FibroBiologics has reported Net Cash Flow for 4 years, with the latest figure at $2.0 million in Q2 2026.
- Net Cash Flow for Q2 2026 came in at $2.0 million, up 1042.13% year-over-year; the trailing twelve-month figure through Jun 2026 was -$5.3 million (down 285.58% YoY), and the FY2025 annual result was -$9.1 million, down 288.53% from the prior year.
- Net Cash Flow advanced to $2.0 million in Q2 2026, from -$3.4 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $12.5 million in Q1 2023 and troughed at -$5.3 million in Q1 2025.
- A 4-year average of $89214.3 and a median of -$808500.0 in 2023 frame the typical range for Net Cash Flow.
- The widest annual swing landed in 2025, when Net Cash Flow plunged 429.15%; it then soared 1042.13% in 2026.
- A 4-year view of Net Cash Flow shows it stood at -$1.6 million in 2023, then surged by 484.15% to $6.2 million in 2024, then tumbled by 99.56% to $27000.0 in 2025, then surged by 7429.63% to $2.0 million in 2026.
- Per Business Quant data, the three most recent Net Cash Flow figures were $2.0 million in Q2 2026, -$3.4 million in Q1 2026, and $27000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 225.59 Mn |
| 10 | FibroBiologics | 9.00 Mn | 9.00 Mn | - | 2.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.03 Mn |
| Jun 30, 2026 | 2.03 Mn |
| Mar 31, 2026 | -3.41 Mn |
| Mar 31, 2026 | -3.41 Mn |
| Dec 31, 2025 | 27,000.00 |
| Dec 31, 2025 | 27,000.00 |
| Sep 30, 2025 | -3.98 Mn |
| Sep 30, 2025 | -3.98 Mn |
| Jun 30, 2025 | 178,000.00 |
| Jun 30, 2025 | 178,000.00 |
| Mar 31, 2025 | -5.32 Mn |
| Mar 31, 2025 | -5.32 Mn |
| Dec 31, 2024 | 6.16 Mn |
| Dec 31, 2024 | 6.16 Mn |
| Sep 30, 2024 | 1.85 Mn |
| Sep 30, 2024 | 1.85 Mn |
| Jun 30, 2024 | -2.19 Mn |
| Jun 30, 2024 | -2.19 Mn |
| Mar 31, 2024 | -1.01 Mn |
| Mar 31, 2024 | -1.01 Mn |